CD19 and neoplasm: Schneider and colleagues developed trispecific CD19-CD20-CD22-targeted CAR-T cells that rapidly and efficiently rejected leukemia and lymphoma tumors in vivo, whereas single-target CAR-T cells failed to inhibit tumor progression [84].